Global Cancer Companion Diagnostic Market Growth (Status and Outlook) 2026-2032

May 2026 | 88 pages | ID: G3C6B72AAC6DEN
LP Information

Abstracts

The global Cancer Companion Diagnostic market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.

The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.

LPI (LP Information)' newest research report, the “Cancer Companion Diagnostic Industry Forecast” looks at past sales and reviews total world Cancer Companion Diagnostic sales in 2025, providing a comprehensive analysis by region and market sector of projected Cancer Companion Diagnostic sales for 2026 through 2032. With Cancer Companion Diagnostic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Companion Diagnostic industry.

This Insight Report provides a comprehensive analysis of the global Cancer Companion Diagnostic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cancer Companion Diagnostic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Companion Diagnostic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Companion Diagnostic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Companion Diagnostic.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Companion Diagnostic market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Polymerase Chain Reaction (PCR)
• “Next Generation” Sequencing (NGS)
• Fluorescence In Situ Hybridization (FISH)
• Immunohistochemistry (IHC)

Segmentation by Application:

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• AmoyDx
• Novogene
• Illumina
• Roche
• Agilent
• Abbott
• Thermo Fisher
• Qiagen
• Guardant Health

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Cancer Companion Diagnostic Market Size (2021-2032)
  2.1.2 Cancer Companion Diagnostic Market Size CAGR by Region (2021 VS 2025 VS 2032)
  2.1.3 World Current & Future Analysis for Cancer Companion Diagnostic by Country/Region (2021, 2025 & 2032)
2.2 Cancer Companion Diagnostic Segment by Type
  2.2.1 Polymerase Chain Reaction (PCR)
  2.2.2 “Next Generation” Sequencing (NGS)
  2.2.3 Fluorescence In Situ Hybridization (FISH)
  2.2.4 Immunohistochemistry (IHC)
  2.2.5 Cancer Companion Diagnostic Market Size by Type
    2.2.5.1 Cancer Companion Diagnostic Market Size CAGR by Type (2021 VS 2025 VS 2032)
    2.2.5.2 Global Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
2.3 Cancer Companion Diagnostic Segment by Application
  2.3.1 Lung Cancer
  2.3.2 Colorectal Cancer
  2.3.3 Breast Cancer
  2.3.4 Others
  2.3.5 Cancer Companion Diagnostic Market Size by Application
    2.3.5.1 Cancer Companion Diagnostic Market Size CAGR by Application (2021 VS 2025 VS 2032)
    2.3.5.2 Global Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)

3 CANCER COMPANION DIAGNOSTIC MARKET SIZE BY PLAYER

3.1 Cancer Companion Diagnostic Market Size Market Share by Player
  3.1.1 Global Cancer Companion Diagnostic Revenue by Player (2021-2026)
  3.1.2 Global Cancer Companion Diagnostic Revenue Market Share by Player (2021-2026)
3.2 Global Cancer Companion Diagnostic Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 CANCER COMPANION DIAGNOSTIC BY REGION

4.1 Cancer Companion Diagnostic Market Size by Region (2021-2026)
4.2 Global Cancer Companion Diagnostic Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cancer Companion Diagnostic Market Size Growth (2021-2026)
4.4 APAC Cancer Companion Diagnostic Market Size Growth (2021-2026)
4.5 Europe Cancer Companion Diagnostic Market Size Growth (2021-2026)
4.6 Middle East & Africa Cancer Companion Diagnostic Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Cancer Companion Diagnostic Market Size by Country (2021-2026)
5.2 Americas Cancer Companion Diagnostic Market Size by Type (2021-2026)
5.3 Americas Cancer Companion Diagnostic Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Cancer Companion Diagnostic Market Size by Region (2021-2026)
6.2 APAC Cancer Companion Diagnostic Market Size by Type (2021-2026)
6.3 APAC Cancer Companion Diagnostic Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Cancer Companion Diagnostic Market Size by Country (2021-2026)
7.2 Europe Cancer Companion Diagnostic Market Size by Type (2021-2026)
7.3 Europe Cancer Companion Diagnostic Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Cancer Companion Diagnostic by Region (2021-2026)
8.2 Middle East & Africa Cancer Companion Diagnostic Market Size by Type (2021-2026)
8.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL CANCER COMPANION DIAGNOSTIC MARKET FORECAST

10.1 Global Cancer Companion Diagnostic Forecast by Region (2027-2032)
  10.1.1 Global Cancer Companion Diagnostic Forecast by Region (2027-2032)
  10.1.2 Americas Cancer Companion Diagnostic Forecast
  10.1.3 APAC Cancer Companion Diagnostic Forecast
  10.1.4 Europe Cancer Companion Diagnostic Forecast
  10.1.5 Middle East & Africa Cancer Companion Diagnostic Forecast
10.2 Americas Cancer Companion Diagnostic Forecast by Country (2027-2032)
  10.2.1 United States Market Cancer Companion Diagnostic Forecast
  10.2.2 Canada Market Cancer Companion Diagnostic Forecast
  10.2.3 Mexico Market Cancer Companion Diagnostic Forecast
  10.2.4 Brazil Market Cancer Companion Diagnostic Forecast
10.3 APAC Cancer Companion Diagnostic Forecast by Region (2027-2032)
  10.3.1 China Cancer Companion Diagnostic Market Forecast
  10.3.2 Japan Market Cancer Companion Diagnostic Forecast
  10.3.3 Korea Market Cancer Companion Diagnostic Forecast
  10.3.4 Southeast Asia Market Cancer Companion Diagnostic Forecast
  10.3.5 India Market Cancer Companion Diagnostic Forecast
  10.3.6 Australia Market Cancer Companion Diagnostic Forecast
10.4 Europe Cancer Companion Diagnostic Forecast by Country (2027-2032)
  10.4.1 Germany Market Cancer Companion Diagnostic Forecast
  10.4.2 France Market Cancer Companion Diagnostic Forecast
  10.4.3 UK Market Cancer Companion Diagnostic Forecast
  10.4.4 Italy Market Cancer Companion Diagnostic Forecast
  10.4.5 Russia Market Cancer Companion Diagnostic Forecast
10.5 Middle East & Africa Cancer Companion Diagnostic Forecast by Region (2027-2032)
  10.5.1 Egypt Market Cancer Companion Diagnostic Forecast
  10.5.2 South Africa Market Cancer Companion Diagnostic Forecast
  10.5.3 Israel Market Cancer Companion Diagnostic Forecast
  10.5.4 Turkey Market Cancer Companion Diagnostic Forecast
10.6 Global Cancer Companion Diagnostic Forecast by Type (2027-2032)
10.7 Global Cancer Companion Diagnostic Forecast by Application (2027-2032)
  10.7.1 GCC Countries Market Cancer Companion Diagnostic Forecast

11 KEY PLAYERS ANALYSIS

11.1 AmoyDx
  11.1.1 AmoyDx Company Information
  11.1.2 AmoyDx Cancer Companion Diagnostic Product Offered
  11.1.3 AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.1.4 AmoyDx Main Business Overview
  11.1.5 AmoyDx Latest Developments
11.2 Novogene
  11.2.1 Novogene Company Information
  11.2.2 Novogene Cancer Companion Diagnostic Product Offered
  11.2.3 Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.2.4 Novogene Main Business Overview
  11.2.5 Novogene Latest Developments
11.3 Illumina
  11.3.1 Illumina Company Information
  11.3.2 Illumina Cancer Companion Diagnostic Product Offered
  11.3.3 Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.3.4 Illumina Main Business Overview
  11.3.5 Illumina Latest Developments
11.4 Roche
  11.4.1 Roche Company Information
  11.4.2 Roche Cancer Companion Diagnostic Product Offered
  11.4.3 Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.4.4 Roche Main Business Overview
  11.4.5 Roche Latest Developments
11.5 Agilent
  11.5.1 Agilent Company Information
  11.5.2 Agilent Cancer Companion Diagnostic Product Offered
  11.5.3 Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.5.4 Agilent Main Business Overview
  11.5.5 Agilent Latest Developments
11.6 Abbott
  11.6.1 Abbott Company Information
  11.6.2 Abbott Cancer Companion Diagnostic Product Offered
  11.6.3 Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.6.4 Abbott Main Business Overview
  11.6.5 Abbott Latest Developments
11.7 Thermo Fisher
  11.7.1 Thermo Fisher Company Information
  11.7.2 Thermo Fisher Cancer Companion Diagnostic Product Offered
  11.7.3 Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.7.4 Thermo Fisher Main Business Overview
  11.7.5 Thermo Fisher Latest Developments
11.8 Qiagen
  11.8.1 Qiagen Company Information
  11.8.2 Qiagen Cancer Companion Diagnostic Product Offered
  11.8.3 Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.8.4 Qiagen Main Business Overview
  11.8.5 Qiagen Latest Developments
11.9 Guardant Health
  11.9.1 Guardant Health Company Information
  11.9.2 Guardant Health Cancer Companion Diagnostic Product Offered
  11.9.3 Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2021-2026)
  11.9.4 Guardant Health Main Business Overview
  11.9.5 Guardant Health Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cancer Companion Diagnostic Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Cancer Companion Diagnostic Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Polymerase Chain Reaction (PCR)
Table 4. Major Players of “Next Generation” Sequencing (NGS)
Table 5. Major Players of Fluorescence In Situ Hybridization (FISH)
Table 6. Major Players of Immunohistochemistry (IHC)
Table 7. Cancer Companion Diagnostic Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Cancer Companion Diagnostic Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
Table 10. Cancer Companion Diagnostic Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Cancer Companion Diagnostic Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)
Table 13. Global Cancer Companion Diagnostic Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Cancer Companion Diagnostic Revenue Market Share by Player (2021-2026)
Table 15. Cancer Companion Diagnostic Key Players Head office and Products Offered
Table 16. Cancer Companion Diagnostic Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Cancer Companion Diagnostic Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Cancer Companion Diagnostic Market Size Market Share by Region (2021-2026)
Table 21. Global Cancer Companion Diagnostic Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Cancer Companion Diagnostic Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Cancer Companion Diagnostic Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Cancer Companion Diagnostic Market Size Market Share by Country (2021-2026)
Table 25. Americas Cancer Companion Diagnostic Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
Table 27. Americas Cancer Companion Diagnostic Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)
Table 29. APAC Cancer Companion Diagnostic Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Cancer Companion Diagnostic Market Size Market Share by Region (2021-2026)
Table 31. APAC Cancer Companion Diagnostic Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Cancer Companion Diagnostic Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Cancer Companion Diagnostic Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Cancer Companion Diagnostic Market Size Market Share by Country (2021-2026)
Table 35. Europe Cancer Companion Diagnostic Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Cancer Companion Diagnostic Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Cancer Companion Diagnostic Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Cancer Companion Diagnostic Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Cancer Companion Diagnostic Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Cancer Companion Diagnostic
Table 41. Key Market Challenges & Risks of Cancer Companion Diagnostic
Table 42. Key Industry Trends of Cancer Companion Diagnostic
Table 43. Global Cancer Companion Diagnostic Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Cancer Companion Diagnostic Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Cancer Companion Diagnostic Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Cancer Companion Diagnostic Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. AmoyDx Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 48. AmoyDx Cancer Companion Diagnostic Product Offered
Table 49. AmoyDx Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. AmoyDx Main Business
Table 51. AmoyDx Latest Developments
Table 52. Novogene Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 53. Novogene Cancer Companion Diagnostic Product Offered
Table 54. Novogene Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. Novogene Main Business
Table 56. Novogene Latest Developments
Table 57. Illumina Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 58. Illumina Cancer Companion Diagnostic Product Offered
Table 59. Illumina Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Illumina Main Business
Table 61. Illumina Latest Developments
Table 62. Roche Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 63. Roche Cancer Companion Diagnostic Product Offered
Table 64. Roche Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Roche Main Business
Table 66. Roche Latest Developments
Table 67. Agilent Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 68. Agilent Cancer Companion Diagnostic Product Offered
Table 69. Agilent Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Agilent Main Business
Table 71. Agilent Latest Developments
Table 72. Abbott Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 73. Abbott Cancer Companion Diagnostic Product Offered
Table 74. Abbott Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Abbott Main Business
Table 76. Abbott Latest Developments
Table 77. Thermo Fisher Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 78. Thermo Fisher Cancer Companion Diagnostic Product Offered
Table 79. Thermo Fisher Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Thermo Fisher Main Business
Table 81. Thermo Fisher Latest Developments
Table 82. Qiagen Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 83. Qiagen Cancer Companion Diagnostic Product Offered
Table 84. Qiagen Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Qiagen Main Business
Table 86. Qiagen Latest Developments
Table 87. Guardant Health Details, Company Type, Cancer Companion Diagnostic Area Served and Its Competitors
Table 88. Guardant Health Cancer Companion Diagnostic Product Offered
Table 89. Guardant Health Cancer Companion Diagnostic Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. Guardant Health Main Business
Table 91. Guardant Health Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Cancer Companion Diagnostic Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cancer Companion Diagnostic Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Cancer Companion Diagnostic Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Cancer Companion Diagnostic Sales Market Share by Country/Region (2025)
Figure 8. Cancer Companion Diagnostic Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Cancer Companion Diagnostic Market Size Market Share by Type in 2025
Figure 10. Cancer Companion Diagnostic in Lung Cancer
Figure 11. Global Cancer Companion Diagnostic Market: Lung Cancer (2021-2026) & ($ millions)
Figure 12. Cancer Companion Diagnostic in Colorectal Cancer
Figure 13. Global Cancer Companion Diagnostic Market: Colorectal Cancer (2021-2026) & ($ millions)
Figure 14. Cancer Companion Diagnostic in Breast Cancer
Figure 15. Global Cancer Companion Diagnostic Market: Breast Cancer (2021-2026) & ($ millions)
Figure 16. Cancer Companion Diagnostic in Others
Figure 17. Global Cancer Companion Diagnostic Market: Others (2021-2026) & ($ millions)
Figure 18. Global Cancer Companion Diagnostic Market Size Market Share by Application in 2025
Figure 19. Global Cancer Companion Diagnostic Revenue Market Share by Player in 2025
Figure 20. Global Cancer Companion Diagnostic Market Size Market Share by Region (2021-2026)
Figure 21. Americas Cancer Companion Diagnostic Market Size 2021-2026 ($ millions)
Figure 22. APAC Cancer Companion Diagnostic Market Size 2021-2026 ($ millions)
Figure 23. Europe Cancer Companion Diagnostic Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Cancer Companion Diagnostic Market Size 2021-2026 ($ millions)
Figure 25. Americas Cancer Companion Diagnostic Value Market Share by Country in 2025
Figure 26. United States Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Cancer Companion Diagnostic Market Size Market Share by Region in 2025
Figure 31. APAC Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
Figure 32. APAC Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)
Figure 33. China Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 37. India Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Cancer Companion Diagnostic Market Size Market Share by Country in 2025
Figure 40. Europe Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
Figure 41. Europe Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)
Figure 42. Germany Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 43. France Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Cancer Companion Diagnostic Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Cancer Companion Diagnostic Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Cancer Companion Diagnostic Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Cancer Companion Diagnostic Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 56. APAC Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 57. Europe Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 59. United States Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 60. Canada Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 61. Mexico Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 62. Brazil Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 63. China Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 64. Japan Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 65. Korea Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 67. India Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 68. Australia Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 69. Germany Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 70. France Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 71. UK Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 72. Italy Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 73. Russia Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 74. Egypt Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 75. South Africa Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 76. Israel Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 77. Turkey Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)
Figure 78. Global Cancer Companion Diagnostic Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Cancer Companion Diagnostic Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Cancer Companion Diagnostic Market Size 2027-2032 ($ millions)